Dana D Byrne1, Craig W Newcomb2, Dena M Carbonari3, Melissa S Nezamzadeh3, Kimberly B F Leidl2, Maximilian Herlim2, Yu-Xiao Yang4, Sean Hennessy3, Jay R Kostman5, Mary B Leonard6, Russell Localio2, Vincent Lo Re7. 1. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 2. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 3. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 4. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 5. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 6. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Division of Nephrology, Department of Pediatrics, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 7. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Electronic address: vincentl@mail.med.upenn.edu.
Abstract
PURPOSE: Few population-based studies have estimated the number of persons diagnosed with chronic hepatitis B (CHB) infection in the United States. Our objective was to estimate the prevalence of diagnosed CHB infection among persons enrolled in the U.S. Medicaid programs of California, Florida, New York, Ohio, and Pennsylvania between 2000 and 2007. As part of our analyses, we confirmed the accuracy of CHB diagnoses within the Medicaid database. METHODS: CHB infection was defined by the presence of two outpatients CHB diagnoses recorded more than 6 months apart. Two clinicians reviewed the medical records of a random sample of patients who met this definition to confirm the diagnosis, which enabled calculation of the positive predictive value (PPV). The period prevalence of diagnosed CHB infection among Medicaid enrollees with at least 6 months of membership from 2000 to 2007 was then estimated, adjusting for both the PPV and estimated sensitivity of our definition of CHB infection. RESULTS: The definition of CHB infection accurately identified clinician-confirmed cases (PPV, 96.3%; 95% confidence interval [CI], 87.3-99.5). Using this definition, 31,046 cases of CHB were diagnosed among 31,358,010 eligible Medicaid members from the five states (prevalence, 9.9 [95% CI, 9.8-10.0] per 10,000). Adjusting for the PPV and estimated sensitivity of our CHB definition, the prevalence of diagnosed CHB infection was 15.6 (95% CI, 15.4-15.7) per 10,000. CONCLUSIONS: Two outpatient CHB diagnoses recorded more than 6 months apart validly identified clinician-confirmed CHB. The prevalence of diagnosed CHB infection among U.S. Medicaid enrollees was 15.6 per 10,000.
PURPOSE: Few population-based studies have estimated the number of persons diagnosed with chronic hepatitis B (CHB) infection in the United States. Our objective was to estimate the prevalence of diagnosed CHB infection among persons enrolled in the U.S. Medicaid programs of California, Florida, New York, Ohio, and Pennsylvania between 2000 and 2007. As part of our analyses, we confirmed the accuracy of CHB diagnoses within the Medicaid database. METHODS:CHB infection was defined by the presence of two outpatients CHB diagnoses recorded more than 6 months apart. Two clinicians reviewed the medical records of a random sample of patients who met this definition to confirm the diagnosis, which enabled calculation of the positive predictive value (PPV). The period prevalence of diagnosed CHB infection among Medicaid enrollees with at least 6 months of membership from 2000 to 2007 was then estimated, adjusting for both the PPV and estimated sensitivity of our definition of CHB infection. RESULTS: The definition of CHB infection accurately identified clinician-confirmed cases (PPV, 96.3%; 95% confidence interval [CI], 87.3-99.5). Using this definition, 31,046 cases of CHB were diagnosed among 31,358,010 eligible Medicaid members from the five states (prevalence, 9.9 [95% CI, 9.8-10.0] per 10,000). Adjusting for the PPV and estimated sensitivity of our CHB definition, the prevalence of diagnosed CHB infection was 15.6 (95% CI, 15.4-15.7) per 10,000. CONCLUSIONS: Two outpatient CHB diagnoses recorded more than 6 months apart validly identified clinician-confirmed CHB. The prevalence of diagnosed CHB infection among U.S. Medicaid enrollees was 15.6 per 10,000.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: G M McQuillan; P J Coleman; D Kruszon-Moran; L A Moyer; S B Lambert; H S Margolis Journal: Am J Public Health Date: 1999-01 Impact factor: 9.308
Authors: Sean Hennessy; Charles E Leonard; Cristin P Freeman; Rajat Deo; Craig Newcomb; Stephen E Kimmel; Brian L Strom; Warren B Bilker Journal: Pharmacoepidemiol Drug Saf Date: 2010-06 Impact factor: 2.890
Authors: N C Tassopoulos; G J Papaevangelou; M H Sjogren; A Roumeliotou-Karayannis; J L Gerin; R H Purcell Journal: Gastroenterology Date: 1987-06 Impact factor: 22.682
Authors: P Coursaget; B Yvonnet; J Chotard; P Vincelot; M Sarr; C Diouf; J P Chiron; I Diop-Mar Journal: J Med Virol Date: 1987-05 Impact factor: 2.327
Authors: D D Byrne; C W Newcomb; D M Carbonari; M S Nezamzadeh; K B F Leidl; M Herlim; Y X Yang; S Hennessy; J R Kostman; M B Leonard; A R Localio; V Lo Re Journal: J Viral Hepat Date: 2015-03-06 Impact factor: 3.728
Authors: Dana D Byrne; Craig W Newcomb; Dena M Carbonari; Melissa S Nezamzadeh; Kimberly B F Leidl; Maximilian Herlim; Yu-Xiao Yang; Sean Hennessy; Jay R Kostman; Mary B Leonard; A Russell Localio; Vincent Lo Re Journal: J Hepatol Date: 2014-04-05 Impact factor: 25.083
Authors: Charles E Leonard; Colleen M Brensinger; Young Hee Nam; Warren B Bilker; Geralyn M Barosso; Margaret J Mangaali; Sean Hennessy Journal: BMC Health Serv Res Date: 2017-04-26 Impact factor: 2.655
Authors: Mindie H Nguyen; Joseph K Lim; A Burak Ozbay; Jeremy Fraysse; Iris Liou; Nicole Meyer; Geoffrey Dusheiko; Stuart C Gordon Journal: Hepatology Date: 2019-02-11 Impact factor: 17.425
Authors: Mei Lu; Yueren Zhou; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Jia Li; Loralee B Rupp; Sheri Trudeau; Stuart C Gordon Journal: Open Forum Infect Dis Date: 2019-06-14 Impact factor: 3.835